UBS Group’s Innoviva INVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-105,800
Closed -$1.48M 8197
2020
Q2
$1.48M Sell
105,800
-385,900
-78% -$5.25M ﹤0.01% 3162
2020
Q1
$5.78M Buy
491,700
+40,600
+9% +$537K ﹤0.01% 1809
2019
Q4
$6.39M Buy
451,100
+358,500
+387% +$4.4M ﹤0.01% 2369
2019
Q3
$976K Buy
+92,600
New +$1.11M ﹤0.01% 3987
2016
Q4
Sell
-114,000
Closed -$1.25M 7884
2016
Q3
$1.25M Buy
+114,000
New +$1.33M ﹤0.01% 3258
2016
Q2
Sell
-116,100
Closed -$1.46M 7839
2016
Q1
$1.46M Buy
+116,100
New +$1.27M ﹤0.01% 2943

Other funds holding INVA

UBS Group's INVA Position: Q1 2026 in Review

UBS Group reduced its Innoviva (INVA) stake by 14% in Q1 2026, selling an estimated $1.53M and leaving 437,093 shares worth $10.2M. The position accounts for ﹤0.01% of the portfolio, ranked #3328.

UBS Group first reported a position in INVA in Q4 2014 and has held it in 46 quarters since. The position peaked at $17M in Q2 2018. 286 funds tracked by Wall St. Rank hold INVA as of Q1 2026.

  • UBS Group held 437,093 shares of Innoviva worth $10.2M as of Q1 2026.
  • UBS Group sold 71,085 Innoviva shares in Q1 2026, an estimated $1.53M.
  • Innoviva made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3328 holding.
  • UBS Group first reported a position in Innoviva in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Innoviva position peaked at $17M in Q2 2018.
  • 286 funds tracked by Wall St. Rank held Innoviva as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.